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1Introduction
Radiotherapy (RT) is an important treatment modality 
in the management of head and neck cancer (HNC). RT 
can be used as a single modality or in combination with 
surgery and/or chemotherapy (CT). One of the most fre-
quently reported side effects following RT in patients with 
HNC is hyposalivation and subsequent xerostomia due 
to co- irradiation of the salivary glands [1, 2]. Xerostomia 
significantly impairs the patient’s quality of life due to 
the many secondary effects such as impairment of taste, 
swallowing, and speech [2–6]. Furthermore, the oral 
mucosa can become dry and atrophic, leading to frequent 
ulceration [6].
Approximately 40% of patients with HNC will experi-
ence xerostomia to some degree after treatment with RT 
[7–11]. The introduction of new techniques such as 
parotid- sparing intensity- modulated RT (IMRT) has 
resulted in less xerostomia; however, toxicity outcome is 
still far from perfect [12]. The Oncology and Radiotherapy 
Group for Head and Neck Cancer (GORTEC) proposed 
to evaluate prospectively acute and late toxicities, locore-
gional control, and overall survival for patients treated 
for head and neck cancer (HNC) with IMRT and bilateral 
neck irradiation in the GORTEC 2004–03 study. It was 
reported that 16.1% of patients treated with parotid- sparing 
IMRT experienced severe xerostomia 18 months after the 
completion of treatment [13].
Xerostomia can occur early during RT treatment. 
Depending on the localization of the tumor and the radia-
tion portals, a rapid decrease of the salivary flow rate is 
observed during the first week of RT, after which there 
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Abstract
Xerostomia is an important complication following radiotherapy (RT) for head 
and neck cancer. Current treatment approaches are insufficient and can only 
temporarily relieve symptoms. New insights into the physiopathology of radiation- 
induced xerostomia might help us in this regard. This review discusses the 
current knowledge of salivary gland stem cells in radiation- induced xerostomia 
and their value in the prevention and treatment of this complication. Salivary 
gland stem cell transplantation, bone marrow- derived cell mobilization, molecular 
regulation of parotid stem cells, stem cell sparing RT, and adaptive RT are 
promising techniques that are discussed in this study.
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is a continuing gradual decrease to less than 10% of the 
initial flow rate. This early reaction is unforeseen because 
the excretory, acinar cells in the salivary glands have a 
slow mitotic rate; a fast response to RT is therefore not 
expected [6, 14]. It is suggested that early damage may 
be due to damage to the plasma membrane of acinar 
cells, compromising the receptor- mediated signaling path-
ways of water excretion. No immediate cell death takes 
place. Late damage, on the other hand, may be explained 
by (DNA) damage to the salivary gland stem cells (SCs) 
and subsequent lack of proper cell renewal [15, 16].
A review of published studies suggested that severe 
xerostomia can be avoided if either the mean dose to 
both parotid glands is less than 25 Gy or one parotid 
gland is spared to a mean dose of less than 20 Gy [17]. 
GORTEC 2004- 03 showed that a mean dose administered 
to the spared parotid below 28 Gy led to significantly 
less severe xerostomia [13].
Following RT, salivary gland recovery is dependent on the 
radiation dose and on the number of remaining viable SCs 
[6]. Increasing the regenerative potential of salivary glands 
by SC therapy after irradiation should be able to restore 
tissue homeostasis [6]. Gaining knowledge in the field of 
salivary gland SCs may thus provide means of preventing 
late xerostomia or could lead to new treatment strategies to 
improve regeneration of these cells after RT. These new treat-
ment approaches are in demand because the current clinical 
management of xerostomia is often difficult and brings in 
many cases no substantial relief for the patient [18].
In 2006, our research group published a literature review 
on radiation- induced xerostomia in patients with head and 
neck cancer [2]. Since this review was published, there 
has been extensive research in the field of xerostomia 
prevention and treatment after RT in head and neck cancer. 
A substantial proportion of this research focused on the 
link between salivary gland SCs and xerostomia. Research 
on salivary gland SCs and treatment strategies regarding 
these cells is scattered in literature. Therefore, we present 
in this review an overview of new findings in this field, 
with emphasis on possible therapeutic applications.
A systematic literature search was performed in the 
MEDLINE/PubMed database for articles published between 
January 1990 and September 2015. The objective was to 
trace all literature containing original data on new find-
ings and potential treatment strategies in the field of 
salivary gland SCs.
The literature search was performed in October 2015 
using combinations of Mesh terms of “xerostomia”, “radio-
therapy”, “salivary gland,” and “stem cell”. Furthermore, 
extensive cross- referencing of the selected articles was 
performed. Case reports were eliminated from this review. 
Furthermore, the search was limited to English language. 
Gender and age were not limited.
Prevention and treatment of 
radiation- induced xerostomia
Stem cell transplantation and bone marrow- 
derived cell mobilization
Stem cell transplantation
Before transplantation of SCs is possible, surgical removal 
of salivary gland tissue before the start of the oncologic 
treatment is needed. Later on, SCs need to be collected. 
The ultimate goal of SC transplantation is regeneration 
of the function of the salivary gland by differentiation of 
these transplanted SCs into functional salivary gland cells 
[19–25].
Since 2004, several studies were performed in which 
submandibular and parotid gland SCs were transplanted 
in animal models after RT [19–25]. The best marker, 
however, to select SCs for transplantation, still remains 
unclear. The most studied marker is c-Kit. [15, 20–22, 
25, 26] Transplantation of c- Kit- positive cells in mice 
submandibular glands can restore function and morphol-
ogy [25, 26]. Interestingly, these c- Kit- positive cells are 
also found in human salivary glands [26]. Whether these 
c- Kit- positive cells in humans have the same regenerative 
potential needs to be investigated.
On the other hand, it is suggested that CD 49f, CD 
29, CD 24, and CD 133 might be used as markers for 
salivary gland SCs in mice [15, 27–30]. The finding of 
these other markers is important because some of the 
cells of the c- Kit- negative population may also have regen-
erative potential, indicating that c- Kit is inadequate as a 
marker and that a combination of markers is needed, 
especially when a low amount of donor material is avail-
able [25].
Side population cells have been identified in various 
organs as putative SCs; their precise function, however, 
remains unclear. In mice salivary glands, side population 
cells did not seem to have SC activity [27]. However, a 
side population cell- derived protein—clusterin—was identi-
fied as a factor to recover from hypofunction of the 
salivary glands. It is believed that clusterin scavenges reac-
tive oxygen species after irradiation [27]. This means that 
this protein might have an additional benefit when stem 
cell transplantation is performed.
Bone marrow- derived cell mobilization
Mesenchymal SCs from the bone marrow can be mobilized 
[31, 32]. After migration, they secrete growth and survival 
factors that enhance the regeneration of tissue by stimu-
lating the proliferation and differentiation of remaining 
salivary gland SCs and by decreasing inflammation and 
modifying the immune response [31]. Importantly, this 
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effect can be mimicked by adding keratinocyte growth 
factor, prophylactic pilocarpine (a nonselective muscarinic 
receptor agonist) or hyperbaric oxygen [23, 33, 34].
Selection of patients for this treatment will be very 
important. When the damage to the salivary gland is 
expected to be low, this technique using bone marrow- 
derived cells could be enough to limit xerostomia after 
RT. When the damage is expected to be high, bone 
marrow- derived cell mobilization could be insufficient, so 
SC transplantation may be necessary [31].
Molecular regulation of salivary gland stem 
cells
Until recent, little was known about the molecular regula-
tors of SCs in human salivary glands. Nowadays, there 
is growing evidence that the Wnt/β- catenin signaling 
pathway is essential for maintenance and activation of 
different types of SCs, including these of the salivary glands 
[35–37]. Regeneration of SCs is impaired by Wnt inhibi-
tion and enhanced by Wnt activation in epithelial organs 
such as the liver, airways, and intestines [38, 39]. The 
central mediator of Wnt signaling is β catenin, which 
acts as an activator of gene transcription.
There is increasing data that activation of this pathway 
may also have a radioprotective effect and might decrease 
xerostomia numbers in irradiated patients [36, 40]. Forced 
activation of the Wnt/β- catenin pathway in mice during 
RT prevents both acute and chronic hyposalivation through 
inhibition of apoptosis and preservation of functional 
salivary stem/progenitor cells [36].
Wnt activation is also known to promote angiogenesis 
and innervation during development. In this regard, it is 
speculated that Wnt activation can help in the regenera-
tion of the damage to blood supply and innervation after 
irradiation. This can play an additional role in the pre-
vention of hyposalivation after RT [41].
These findings are promising; however, further research 
is mandatory to confirm the results and to investigate 
whether activation of this pathway is sufficient to prevent 
xerostomia in humans after RT.
Regarding the introduction of this technique, a major 
concern that needs further clarification is that overexpres-
sion of the Wnt/β- catenin pathway has been linked to 
carcinogenesis [42].
Furthermore, there is emerging evidence that transient 
activation of the Hedgehog pathway and modulation of 
the GDNF pathway might play a role in preserving salivary 
gland SCs after RT [30, 43–45]. An overview of all the 
cross talking intercellular signaling pathways involved in 
the development and regeneration of salivary gland SCs 
is beyond the scope of this study but can be found in 
a recent review by Liu et al. [43].
Bath and shower principle in RT
Intensity- modulated RT (IMRT) is the modality of choice 
to reduce xerostomia numbers following RT for HNC 
[12]. Minimization of the mean dose to the parotid glands 
is the preferred technique to achieve parotid gland func-
tion sparing [13, 17]. In spite of technical improvements, 
xerostomia after IMRT remains a serious problem [12].
A first possible explanation for this higher- than- expected 
incidence of xerostomia is the hypothesis that radiation 
of the parotid gland has a “bath and shower effect”. 
Photon- based IMRT gives an overall low dose to the entire 
parotid gland [46]. There is evidence that the tolerance 
to a high dose of RT to a small subvolume (“shower”) 
is strongly reduced by giving a subtolerance dose to the 
surrounding volume (“bath”) [46]. Van Luijk et al. dem-
onstrated this in the parotid gland in a rat model [46]. 
The parotid glands were irradiated up to a dose of 10 Gy, 
which did not result in late loss of function. Addition of 
a bath of 1–10 Gy to the caudal 50% of the glands resulted 
in enhanced function loss. This indicates that avoiding an 
overall low dose to the parotid gland in rats could lead 
to less parotid gland hypofunction and subsequently to 
less xerostomia. Recovery after RT appears to be depend-
ent on the number of remaining SCs after treatment [25]. 
Currently, we have no good idea about the radiosensitivity 
of parotid gland SCs; however, the results above are sug-
gesting that these SCs are very radiosensitive. High- precision 
RT, avoiding low doses to the entire parotid gland, can 
possibly counteract this problem. Proton RT, for example, 
has a steeper dose gradient, and could therefore avoid a 
low dose to the surrounding tissues more easily.
Sparing of SC- rich regions in the parotid 
gland during RT
Sparing of SC- rich regions within the parotid gland could 
help in preventing xerostomia following RT [47]. The 
specific location of these SCs and therefore the region to 
spare has been the subject of debate. Several research 
groups found that (c- Kit positive) stem/progenitor cells 
in the salivary gland are located in the larger excretory 
ducts [47, 48]. Van Luijk et al. investigated the relation-
ship between the localization of parotid SCs and late 
parotid gland dysfunction after irradiation in a rat model 
[46, 47]. They found a correlation in the rat model where 
high- precision irradiation to the center of the parotid 
gland resulted in excessive reduction of saliva production, 
indicating that this zone contains a large population of 
SCs. The dose to specific volumes of the parotid gland 
was also correlated by this research group to saliva pro-
duction 1 year after RT. This research group showed in 
a cohort of patients with HNC that the RT dose to the 
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region of the salivary gland containing stem/progenitor 
cells predicted the function of the salivary glands 1 year 
after RT [47]. Miah et al. found that sparing the super-
ficial lobe of both parotid glands may offer a higher 
incidence of recovery of salivary function compared to 
whole contralateral parotid gland sparing alone in oro-
pharyngeal cancers [48]. Buettner et al. found similar 
results [49]. In our department, we conducted a study 
in which we included 28 patients who were treated with 
chemoradiotherapy (CRT) for HNC. We looked at the 
mean radiation dose to the superficial and deep ipsilateral 
parotid lobe and correlated this with patient- and physician- 
scored xerostomia. In this small patient group, we observed 
a significant correlation between physician- scored xeros-
tomia ≥2 and the mean dose to the ipsilateral superficial 
parotid lobe. Sparing of the superficial ipsilateral parotid 
lobe, while sparing the whole contralateral parotid gland, 
could mean a step forward toward decreasing xerostomia 
after RT for HNC (unpublished data). We will investigate 
this hypothesis further in a larger patient cohort.
Sparing of the submandibular gland and 
oral cavity during RT
Dijkema et al. stated that sparing of the contralateral sub-
mandibular gland, in addition to parotid gland sparing, 
might result in improved patient- reported xerostomia [50]. 
Little et al. found that mean doses to the parotid glands, 
submandibular glands, and oral cavity are significant pre-
dictors of both patient- reported and observer- rated xeros-
tomia after chemo- IMRT, with oral cavity doses remaining 
significant after adjusting for the parotid gland and sub-
mandibular gland doses [51]. Jellema et al. found that the 
mean dose to the parotid and submandibular glands could 
influence the risk of xerostomia at 6 months; no significant 
differences were found when xerostomia was correlated 
with the oral cavity dose [9]. These results, however, sup-
port efforts to spare all the salivary glands as much as 
possible [51]. Mean RT doses to the submandibular gland 
exceeding 39 Gy cause permanent ablation of both stimu-
lated and unstimulated flow [52]. These findings are prom-
ising. It might be interesting to combine research on sparing 
of the submandibular gland and oral cavity with sparing 
of SC- rich regions in the parotid gland during RT.
Adaptive RT
One of the unique aspects of RT to the head and neck 
region is that noticeable changes in the anatomy occur 
during treatment. These changes include shrinkage of the 
tumor, but also of the surrounding organs at risk (such 
as the parotid and submandibular glands) [53]. Furthermore, 
a medial shift of the parotid glands is often described 
during RT [54]. A small study of our research group includ-
ing five patients showed a median relative volume loss of 
the parotid glands of 41.5% during RT (range 20.0–48.4%). 
The parotid glands generally shifted medially due to tumor 
shrinkage and weight loss. Therefore, the plan created on 
the initial planning computed tomography may no longer 
be optimal for the changed anatomy during treatment. 
Moreover, the actual RT dose delivered to the patients 
may be significantly different from what was planned. 
Computed tomographies taken during the course of RT 
could be used to evaluate at what point in time the target 
volume, organs at risk and dose distribution have changed 
to such an extent that replanning is necessary [53]. This 
adaptive approach could result in less irradiation of the 
organs at risk and thus less irradiation of the parotid SCs.
We recently closed a multicenter randomized adaptive 
radiotherapy trial including 100 patients with HNC. All 
patients received a computed tomography at 2 and 4 
weeks after start of treatment, replanning was performed 
at these time-points. Further follow- up of these patients 
will give us more insights into whether this adaptive RT 
technique results in less xerostomia.
Conclusions
To date, none of the described techniques concerning SCs 
to treat xerostomia are ready for clinical implementation, 
although most of them seem very promising in animal 
models.
It will become clear in future trials which technique 
or combination of techniques will be the most beneficial, 
cost- effective, and easy to implement. The emphasis, nev-
ertheless, has to be on avoiding xerostomia as much as 
possible. If both the shower and bath assumption, the 
role of the contralateral submandibular gland and the 
importance of SC sparing RT are confirmed in future 
trials, high- specific proton RT could be a way to coun-
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